Also, mTOR was shown to regulate the effector fate of CD8+ T cells during tumor immunity and infections.207 Interestingly, several studies have primarily focused on mTOR inhibitor rapamycin’s ability to hinder T-cell proliferation and IL-2 production and induce anergy (a cellular state when the lymphocytes fail to respond upon stimulation), even in adequately stimulated T cells.196,198,205 Upon T-cell receptor (TCR) stimulation, both mTORC1 and mTORC2 are activated. The gene discussed is CD8A; the disease is neoplasm.